Headquarters: Cambridge, Massachusetts, USA
Ticker: VYTR (NASDAQ)
Founded: 2013
Pipeline Focus: Gene therapy for neurological disorders
Voyager Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases, with a particular emphasis on Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions. The company leverages its proprietary AAV vector platform and strategic partnerships to develop transformative therapies that address the underlying causes of neurological disorders.
Voyager's most advanced program, VY-AADC (also known as VYNAV-301), is a gene therapy for Parkinson's disease that aims to restore dopamine production by delivering the aromatic L-amino acid decarboxylase (AADC) gene directly to the striatum. This approach offers the potential for long-lasting symptom relief from a single treatment.
Mechanism: AAV2-hAADC gene therapy delivering functional AADC enzyme to striatal neurons
Stage: Phase 1
Status: Clinical
VY-AADC is Voyager's lead gene therapy program for Parkinson's disease. By delivering the AADC gene directly to the striatum, the therapy enables neurons that have lost dopamine-producing capacity to again synthesize dopamine, addressing the root cause of motor symptoms.
Clinical Development:
- Phase 1: Completed, demonstrating safety and proof-of-concept
- Phase 1b: Long-term follow-up showing sustained benefits
- Ongoing studies in advanced Parkinson's disease
Key Findings:
- Durable motor symptom improvement observed in patients
- Reduced levodopa requirements post-treatment
- Favorable safety profile with no serious adverse events related to treatment
Mechanism: Undisclosed gene therapy target
Stage: Preclinical
Status: Research
VY-FYN is Voyager's second Parkinson's disease program, targeting an undisclosed mechanism. The program is in preclinical development.
| Program |
Indication |
Stage |
| VY-HTT01 |
Huntington's disease |
Phase 1 |
| VY-TAU |
Alzheimer's disease |
Preclinical |
| VY-ABCA1 |
Alzheimer's disease |
Discovery |
Voyager's proprietary AAV platform enables:
- Enhanced CNS Targeting: Improved delivery to specific brain regions
- Dose Optimization: Reduced required doses while maintaining efficacy
- Manufacturing Efficiency: Scalable production processes
- Novel Capsids: Next-generation vectors with improved transduction
Neurocrine Biosciences Partnership:
- Strategic collaboration for VY-AADC development and commercialization
- Neurocrine has exclusive option to acquire Voyager's Parkinson's disease programs
- Collaboration provides additional development and commercialization expertise
AbbVie Partnership:
- Partnership for tau programs in Alzheimer's disease
- Includes development and commercialization rights for VY-TAU
¶ Business and Financials
- 2013: Founded with $45M Series A funding
- 2015: $60M Series B funding
- 2017: $37M Series C funding
- 2019: $65M Series D funding
- 2021: IPO raised $91M
- Current Market Cap: ~$350 million (2024)
- Strategic partnerships provide non-dilutive funding
- Focus on capital efficiency with lean operations
The Phase 1 trial of VY-AADC demonstrated:
- Motor Improvement: Significant improvements in OFF-medication Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores
- Durability: Benefits maintained through 3+ years of follow-up
- Levodopa Reduction: Patients achieved reduced levodopa requirements
- Safety: No dose-limiting toxicities observed
These results support the potential for VY-AADC to provide meaningful, long-lasting benefits for patients with advanced Parkinson's disease.
¶ Research and Development Focus
Voyager's R&D strategy emphasizes:
- Gene Replacement: Delivering functional copies of disease-causing genes
- Gene Silencing: Using RNA interference to reduce toxic protein expression
- Target Validation: Rigorous validation of therapeutic targets before clinical development
- Combination Approaches: Exploring gene therapy combinations for enhanced efficacy
- CEO: Michael J. (former Biogen executive)
- CSO: Dr. James M. (gene therapy pioneer)
- CMO: Dr. Mark A. (former FDA reviewer)
- Board: Includes scientific founders from Harvard and Massachusetts General Hospital